Core Insights - A new rapid antidepressant strategy has been proposed by a collaborative team from Hefei Comprehensive National Science Center and other institutions, leading to the development of a candidate compound TMU4142, which shows significant rapid antidepressant effects in animal tests without notable side effects, providing a new approach for the development of next-generation rapid antidepressants [1][3] Group 1: Antidepressant Research - Depression is a major global mental health burden affecting over 300 million people, with existing mainstream antidepressants like SSRIs having significant drawbacks, including delayed onset of effects [1] - The delay in drug efficacy is attributed to the negative feedback inhibition effect of serotonin 1A autoreceptors in the dorsal raphe nucleus, which suppress serotonin release, leading to a lag in therapeutic effects [2] Group 2: Mechanism and Development - The research team identified that serotonin 1A receptors in different brain regions preferentially couple with different G proteins, which can be leveraged to design a compound that selectively activates the GoA protein while minimizing activation of the Gi3 protein, thus avoiding the negative feedback effect [2] - The candidate compound TMU4142 was optimized from the reference molecule Pindolol, demonstrating improvement in depressive states in mice within one hour of injection, and it does not trigger the negative feedback mechanism at therapeutic doses [3] Group 3: Future Directions - The research team plans to continue optimizing the compound and conduct systematic preclinical studies, aiming to advance TMU4142 into clinical trials to provide new hope for patients with depression [3]